About: Emerging strategies on in silico drug development against COVID-19: challenges and opportunities

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Emerging strategies on in silico drug development against COVID-19: challenges and opportunities Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Emerging strategies on in silico drug development against COVID-19: challenges and opportunities
Creator	Dhagat, Swasti Yadav, Manisha Satya Eswari, J
topic	covid:8ce91a7f6f43b0afaf334c9bfb556d38f50cf433#this
Source	Elsevier; Medline; PMC
abstract	The importance of coronaviruses as human pathogen has been highlighted by the recent outbreak of SARS-CoV-2 leading to the search of suitable drugs to overcome respiratory infections caused by the virus. Due to the lack of specific drugs against coronavirus, the existing antiviral and antimalarial drugs are currently being administered to the patients infected with SARS-CoV-2. The scientists are also considering repurposing of some of the existing drugs as a suitable option in search of effective drugs against coronavirus till the establishment of a potent drug and/or vaccine. Computer-aided drug discovery provides a promising attempt to enable scientists to develop new and target specific drugs to combat any disease. The discovery of novel targets for COVID-19 using computer-aided drug discovery tools requires the knowledge of structure of the coronavirus and the various target proteins present in the virus. Targeting the viral proteins will make the drug specific against the virus, thereby, increasing the chances of viral mortality. Hence, this review provides the structure of SARS-CoV-2 virus along with the important viral components involved in causing infection. It also focuses on the role of various target proteins in disease, the mechanism by which currently administered drugs act against the virus and the repurposing of few drugs. The gap arising from the absence of specific drugs is addressed by proposing potential antiviral drug targets which might provide insights into structure-based drug development against SARS-CoV-2.
has issue date	2020-08-20(xsd:dateTime)
bibo:doi	10.1016/j.ejps.2020.105522
bibo:pmid	32827661
has license	no-cc
sha1sum (hex)	8ce91a7f6f43b0afaf334c9bfb556d38f50cf433
schema:url	https://doi.org/10.1016/j.ejps.2020.105522
resource representing a document's title	Emerging strategies on in silico drug development against COVID-19: challenges and opportunities
has PubMed Central identifier	PMC7438372
has PubMed identifier	32827661
schema:publication	Eur J Pharm Sci
resource representing a document's body	covid:8ce91a7f6f43b0afaf334c9bfb556d38f50cf433#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/8ce91a7f6f43b0afaf334c9bfb556d38f50cf433
is schema:about of	named entity 'protein' named entity 'prodrug' named entity 'virus' named entity 'protease' named entity 'RNA-directed RNA polymerase' named entity 'favipiravir' named entity 'R441' named entity 'multiple organ failure' named entity 'phase IV' named entity 'organelles' named entity 'prognosis' named entity 'intracellular trafficking' named entity 'interleukin 6' named entity 'viral entry' named entity 'SARS' named entity 'glutathione S-transferase' named entity 'endosomes' named entity 'infection' named entity 'synergistic' named entity 'umifenovir' named entity 'drug designing' named entity 'hydroxychloroquine' named entity 'Chloroquine' named entity 'extracellular space' named entity 'systemic lupus erythematosus' named entity 'SARS-CoV-2' named entity 'peptide' named entity 'dimerization' named entity 'drug development' named entity 'gene' named entity 'lysosomes' named entity 'April 2020' named entity 'cytoplasmic domain' named entity 'clinical trials' named entity 'apoptosis' named entity 'spike protein' named entity 'genetic drift' named entity 'proinflammatory cytokine' named entity 'passive diffusion' named entity 'caspofungin' named entity 'coronavirus' named entity 'protein' named entity 'viral genome' named entity 'virus' named entity 'COVID' named entity '3CLpro' named entity 'SARS-CoV' named entity 'Crystal structure' named entity 'virus' named entity 'influenza virus' named entity 'SARS-CoV' named entity 'dCTP' named entity 'lopinavir' named entity 'drug resistance' named entity 'World Health Organization' named entity 'PDB' named entity 'receptor' named entity 'polymerase' named entity 'host cells' named entity 'drug discovery' named entity 'coronavirus infection' named entity 'coronaviruses' named entity 'SARS-CoV-2' named entity 'receptor' named entity 'OC43' named entity 'genomic sequence' named entity 'drug designing' named entity 'host-cell' named entity 'protein' named entity 'COVID-19' named entity 'PDB' named entity 'hydrophobic' named entity 'chloroquine' named entity 'CoV' named entity 'virus' named entity 'virus' named entity 'Wrapp'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software